By: Barbara Laidlaw and Josiah Adams
The COVID-19 pandemic has often created more questions than answers. From the pandemic’s onset in March, public officials, scientists and healthcare providers have searched with frustration for solutions to the virus’ spread, treatments and, above all else, a potential vaccine.
As we enter the fall and winter months, more people will stay indoors, which experts point to as a potential cause for a second surge of the virus. In metropolitan areas like New York City, this could have catastrophic and long-lasting effects on economic and public health. The potential for a second surge, combined with nationwide political pressure leading up to the November election, has led to increased demand for development and deployment of a COVID-19 vaccine.
Unfortunately, developing a vaccine is a process that can only be fast-tracked so much before becoming dangerous and irresponsible. Brands and organizations must understand the facts surrounding a potential vaccine and make the appropriate business decisions based on them. Otherwise, they run the risk of jeopardizing months of precautions and exposing themselves to significant reputational risk.
President Donald Trump’s administration has issued conflicting messages about the COVID-19 vaccine rollout. On Sept. 21, Dr. Moncef Slaoui —the head of the administration’s COVID-19 vaccine program— told reporters the U.S. could immunize those “most susceptible” to coronavirus by December if there is prior vaccine approval. Yet, the FDA recently announced it would roll out higher safety standards for the vaccine approval process that would make approval unlikely before Nov. 3.